HADLIMA is a tumor necrosis factor (TNF) blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking HADLIMA if you have any kind of infection …

Learn more about HADLIMA™ (adalimumab-bwwd), an FDA-approved biosimilar of HUMIRA (adalimumab), and find resources for your patients and office.

Dec 20, 2022 · Learn about Hadlima (adalimumab) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives.

HADLIMA is a tumor necrosis factor (TNF) blocker indicated for Rheumatoid Arthritis (RA) (1 1): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of...

Dec 7, 2025 · HADLIMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.

Jul 16, 2024 · If a patient or caregiver is to administer HADLIMA, instruct them in injection techniques and assess their ability to inject subcutaneously to ensure the proper administration of HADLIMA …

HADLIMA is a tumor necrosis factor (TNF) blocker indicated for Rheumatoid Arthritis (RA) (1.1): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of …

CVS Health delivered a smooth transition to lower-cost biosimilars with clear communication, expert support, and reliable access.

4 days ago · Organon’s 2025 revenue and earnings softened, with $6.2 billion sales. Q4 weakness in women’s health and margins was partly offset by biosimilars growth. Looking for the best stocks to …

5 days ago · The biosimilar segment exceeded expectations, bolstered by Hadlima and new product launches. Organon is focusing on debt reduction by reducing dividend payouts and divesting non …